Cytisine
Cravv
- Dosage form
- Tablet
- Available strengths
- 1.5 mg
- Drug class
- Nicotinic acetylcholine receptor partial agonist (plant-derived alkaloid) -- smoking-cessation aid
- Common brand
- Cravv
Clinical overview. Cytisine (Cravv) is a plant-derived, non-prescription nicotinic acetylcholine receptor partial agonist licensed in Canada as a natural health product for smoking cessation. It shares its mechanism with varenicline and is taken on a tapering 25-day dosing course (or an alternative 3 mg three-times-daily, 12-week regimen), with a target quit date on day 5 of the traditional schedule.
Indication
Common therapeutic uses
- Licensed in Canada as a natural health product to assist with smoking cessation, used as an aid to reduce nicotine cravings and withdrawal symptoms during a quit attempt.
- Available without a prescription.
Pregnancy
Risk assessment and monitoring considerations
- Safety in pregnancy has not been established; behavioural counselling and, if pharmacotherapy is needed, better-studied agents are generally preferred -- discuss with the prescriber before use in pregnancy.
Breastfeeding
Infant exposure considerations
- Safety during breastfeeding has not been established.
Geriatrics
Dosing and tolerability considerations
- No specific dose adjustment established; use standard adult dosing.
Pediatrics
Use in children and adolescents
- Not established for use under 18 years of age.
Dosage & Administration
Practical dosing and administration
- Traditional 25-day tapering course, started while the patient continues to smoke, with a target quit date on day 5.
- Days 1-3: 1.5 mg (1 capsule) every 2 hours while awake, up to 6 capsules/day, while gradually reducing cigarette intake.
- Days 4-12: 1.5 mg (1 capsule) every 2.5 hours, up to 5 capsules/day.
- Days 13-16: 1.5 mg (1 capsule) every 3 hours, up to 4 capsules/day.
- Days 17-20: 1.5 mg (1 capsule) every 5 hours, up to 3 capsules/day.
- Days 21-25: 1.5-3 mg (1-2 capsules)/day, then discontinue.
- Alternative regimen: 3 mg (2 capsules) 3 times daily for 12 weeks (a less frequent, longer-duration schedule).
- Take with a full glass of water; avoid taking within 1 hour of eating a large meal.
Overdose
Recognizing and responding to overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Nicotinic-receptor-agonist toxicity can occur with excessive doses: nausea, vomiting, headache, dizziness, tachycardia, and, in severe cases, seizures or respiratory depression. Seek medical attention for suspected overdose.
Common side effects
Frequently reported tolerability concerns
- Gastrointestinal upset, nausea, vomiting.
- Sleep disturbances, including abnormal dreams.
- Headache.
Serious side effects
Findings that may require urgent assessment
Serious side effects require immediate discussion with the prescriber or emergency care.
- Rare reports of mood or behavioural changes; theoretical risk given its shared mechanism with varenicline -- monitor patients with a psychiatric history closely.
- Seek urgent care for a seizure, severe allergic reaction, or new or worsening suicidal thoughts.
Use with caution
Situations requiring closer assessment
- Use with caution and closer monitoring in patients with a history of psychiatric disorders.
- Cardiovascular disease -- data are more limited than for varenicline or NRT; use clinical judgment.
Contraindications
Situations where therapy may be inappropriate
- Known hypersensitivity to cytisine or any component of the formulation.
Drug interactions
Clinically relevant combinations
- Combining with varenicline is not recommended, since both act on the same nicotinic receptor pathway.
- No other clinically significant drug interactions have been established; as with all smoking-cessation therapies, stopping smoking itself (independent of cytisine) can raise serum levels of some CYP1A2-cleared drugs.
Food interactions
Meal-related administration
- No significant food interaction identified; take with a full glass of water.
Time of administration
Practical scheduling
- Multiple times daily on a tapering schedule (see Dosage & Administration) -- using a phone alarm or dosing chart to track the changing schedule is recommended.
Storage
Product handling
- Store at room temperature, out of reach and sight of children.
Patient take-away
Key counselling points for a quick closing summary
- Follow the exact tapering schedule -- the number of capsules and time between doses changes throughout the 25-day course.
- Set your quit date for day 5 of treatment, while continuing to gradually cut down beforehand.
- This product is available without a prescription, but tell your pharmacist you are using it so it can be checked against your other medicines.
- Seek urgent care for a seizure, a severe allergic reaction, or new or worsening thoughts of self-harm.
References
Source material and product information
For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.